InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
April 30, 2024 07:30 ET
|
InflaRx N.V.
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
Amesite Launches AI and Technical Training Programs with Volunteer State Community College
April 30, 2024 07:30 ET
|
Amesite Inc.
DETROIT, April 30, 2024 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education...
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
April 30, 2024 07:30 ET
|
Daré Bioscience, Inc.
$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments...
REPEAT - Complete Solaria Names T.J. Rodgers CEO
April 30, 2024 07:30 ET
|
Complete Solaria Inc.
Complete Solaria names T.J. Rodgers as CEO; Promotes Brian Wuebbels to COO.
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
April 30, 2024 07:30 ET
|
XOMA Corporation
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone...
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
April 30, 2024 07:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
April 30, 2024 07:30 ET
|
Invivyd
Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel monoclonal antibodiesCompany now expects...
Dragonfly Energy Partners with the National Forest Foundation to Plant Trees in Honor of Earth Day
April 30, 2024 07:30 ET
|
Dragonfly Energy Holdings Corp.
Dragonfly Energy partners with National Forest Foundation to plant 10 trees for every battery sold, in honor of Earth Day.
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
April 30, 2024 07:30 ET
|
MiNK Therapeutics
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology
April 30, 2024 07:30 ET
|
BioRestorative Therapies, Inc
— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform — — Exclusive, five (5)-year agreement includes...